Novartis expands in radio-oncology again with $1.3bn Artios alliance

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus alliance with UK biotech Artios Pharma to develop precision medicines for cancer.